Search Result

Results for "

triglyceride (TG)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (2) AMPK (1) Biochemical Assay Reagents (3) Drug Derivative (1) Drug Metabolite (1) Endogenous Metabolite (14) Ferroptosis (3) Fluorescent Dye (3) Glutathione Peroxidase (3) GPR109A (1) Isotope-Labeled Compounds (1) LDLR (3) Nuclear Hormone Receptor 4A/NR4A (1) PCSK9 (2) PPAR (1) Proton Pump (1) Reactive Oxygen Species (ROS) (3) Reference Standards (2)
By Research Areas:	Cardiovascular Disease (6) Inflammation/Immunology (3) Metabolic Disease (30)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Microsomal Triglyceride Transfer Protein (MTP) ATGL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112540B

Acetoacetic acid sodium	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .

HY-112540

Acetoacetic acid 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .

HY-112540A

Acetoacetic acid lithium 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-W015600

2-Acetamidophenol Orthocetamol	Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR	Cardiovascular Disease Inflammation/Immunology
2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC₅₀s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe ²⁺), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

HY-110381

JNJ-DGAT2-A	Acyltransferase	Metabolic Disease
JNJ-DGAT2-A is a selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC₅₀ value of 0.14 μM in human DGAT2-expressing Sf9 insect cell membranes. JNJ-DGAT2-A can be used for the research of triglyceride (TG) synthesis .

HY-N15875

18:1-18:1-C11 BODIPY 505/515 TG	Fluorescent Dye	Metabolic Disease
18:1-18:1-C11 BODIPY 505/515 TG is a fluorescently-labeled triglyceride that can be used as a fluorescent probe (Ex/Em = 495/503 nm).

HY-W587772

Mono(2-ethyl-5-hydroxyhexyl) terephthalate MEHHTP	Drug Metabolite	Metabolic Disease
Mono (2-ethyl-5-hydroxyhexyl) terephthalate (MEHHTP), a hydroxyl metabolite of the phthalate alternative Di-2-ethylhexyl terephthalate (DEHTP), is a liver X receptor α (LXRα) agonist with a binding energy of -7.41 kcal/mol. Mono (2-ethyl-5-hydroxyhexyl) terephthalate upregulates LXRα downstream targets such as SREBP-1c and FASN and increases lipogenic enzyme activity in hepatocytes, and elevating triglyceride (TG) levels. Mono (2-ethyl-5-hydroxyhexyl) terephthalate is promising for research of nonalcoholic fatty liver disease (NAFLD) .

HY-W015600R

2-Acetamidophenol (Standard) Orthocetamol (Standard)	Reference Standards Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR	Cardiovascular Disease Inflammation/Immunology
2-Acetamidophenol (Standard) is the analytical standard of 2-Acetamidophenol. This product is intended for research and analytical applications. 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC₅₀s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe ²⁺), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-175725

NR4A1 agonist 1	Nuclear Hormone Receptor 4A/NR4A	Metabolic Disease
NR4A1 agonist 1 is a NR4A1 agonist with a K_i value of 2.96 μM. NR4A1 agonist 1 exhibits lipid-lowering activity in 3T3-L1 adipocytes, with an EC₅₀ of 0.13 μM, significantly decreasing triglyceride (TG) accumulation and lipid droplet accumulation. NR4A1 agonist 1 can be used for the study of obesity .

HY-W015600S

2-Acetamidophenol-d3 Orthocetamol-d₃	Isotope-Labeled Compounds Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR	Cardiovascular Disease Inflammation/Immunology
2-Acetamidophenol-d₃ (Orthocetamol-d₃) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-172083

15:0-18:1-15:0 TG 1,3-Dipentadecanoyl-2-oleoyl-glycerol	Biochemical Assay Reagents	Metabolic Disease
15:0-18:1-15:0 TG (1,3-Dipentadecanoyl-2-oleoyl-glycerol) is a triglyceride .

HY-158614

1-Palmitoyl-2-12-PAHSA-3-oleoyl-sn-glycerol 16:0-12-PAHSA-18:1-TG; TG(16:0/12-PAHSA/18:1)	Endogenous Metabolite	Others
1-Palmitoyl-2-12-PAHSA-3-oleoyl-sn-glycerol (16:0-12-PAHSA-18:1-TG) is a FAHFAs-containing triglyceride that can be synthesized from isotope-labeled FAHFAs, whose decomposition can regulate intracellular FAHFAs levels, and is the major reservoir of FAHFAs in cells and tissues, revealing the activity of a new branch of TG and FAHFAs metabolism.

HY-W704600

1,3-Distearoyl-2-oleoyl glycerol TG(18:0/18:1/18:0)	Biochemical Assay Reagents	Others
1,3-Distearoyl-2-oleoyl glycerol (TG(18:0/18:1/18:0)) is a triglyceride that can be isolated from native fats such as such as kokum, shea butter and mango kernel fat. 1,3-Distearoyl-2-oleoyl glycerol is widely used in the chocolate industry as a cocoa butter modifier and an anti-blooming agent .

HY-176817

GPR109 receptor agonist-3	GPR109A	Cardiovascular Disease Metabolic Disease
GPR109 receptor agonist-3 is an orally active GPR109 receptor agonist, with an IC₅₀ of 310 nM. GPR109 receptor agonist-3 retains the antioxidation and cytoprotection of Lipoic acid (HY-18733). GPR109 receptor agonist-3 reduces total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and increases high-density lipoprotein cholesterol (HDL-C) in high-fat diet-fed rats. GPR109 receptor agonist-3 can be used for the study of atherosclerosis .

HY-N15883

18:1-C11 BODIPY 505/515-C11 BODIPY 505/515 TG	Fluorescent Dye	Metabolic Disease
18:1-C11 BODIPY 505/515-C11 BODIPY 505/515 TG is a fluorescently-labeled triglyceride that can be used to measure triacylglycerol hydrolases (Ex/Em = 495/503 nm) .

HY-161939

7030B-C5	PCSK9	Cardiovascular Disease
7030B-C5 is a PCSK9 inhibitor (IC₅₀=1.61 μM). 7030B-C5 can significantly reduce plasma cholesterol and triglyceride (TG) levels in vivo and slow the progression of atherosclerosis. 7030B-C5 can be used in the study of cardiovascular diseases .

HY-123765

JTT-553	Acyltransferase	Metabolic Disease
JTT-553 is a DGAT1 inhibitor (IC₅₀: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM) .

HY-115705

1,2,3-Tri-10(Z)-heptadecenoyl glycerol Glycerol tri-10(Z)-heptadecenoate; TG(17:1/17:1/17:1); Tri-10(Z)-heptadecenoin	Biochemical Assay Reagents	Others
1,2,3-Tri-10(Z)-heptadecenoyl glycerol (TG(17:1/17:1/17:1)) is a biochemical assay reagent, which can be used as an internal standard for the quantification of biological triglyceride .

HY-165050

1,3-Dilinoleoyl-2-stearoyl glycerol 18:2/18:0/18:2-TG; TG(18:2/18:0/18:2)	Others	Others
1,3-Dilinoleoyl-2-stearoyl glycerol (18:2/18:0/18:2-TG) is a compound used in the study of triglyceride composition of vegetable oils. It was analyzed by supercritical CO? chromatography-mass spectrometry to determine its content and characteristics in different vegetable oils.

HY-N15876

18:1-6:0 DNP-C11 BODIPY 505/515 TG	Fluorescent Dye	Metabolic Disease
18:1-6:0 DNP-C11 BODIPY 505/515 TG is a fluorescently-labeled triglyceride that can be used to study the effects of phosphoinositides (Ex/Em = 495/503 nm) .

HY-N11551

Salvifaricin	Others	Others Metabolic Disease
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-117110

Arginylproline H-Arg-Pro-OH	Proton Pump	Metabolic Disease
Arginylproline (H-Arg-Pro-OH) is a dipeptide consisted of arginine and proline. Arginylproline reduces intracellular triglyceride (TG) levels stimulated by Oleic acid (HY-N1446), through the peptide transporter 1 (PepT1) pathway .

HY-N8214

Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside	Others	Cardiovascular Disease
Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside is a bioactive constituent that can be found in the seeds of Lepidium apetalum Willd. Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside exhibits significant triglyceride (TG)-lowering effects in HepG2 cells .

HY-N7907

Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside	Others	Metabolic Disease
Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside is a natural product that can be obtained from sphaerophysa salsula. Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside inhibits triglyceride (TG) accumulation in 3T3-L1 adipocytes .

HY-146398

AMPK activator 6	AMPK	Metabolic Disease
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .

HY-161985

PPARγ-IN-3	PPAR	Metabolic Disease
PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .

HY-112540AR

Acetoacetic acid lithium (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease
Acetoacetic acid (lithium) (Standard) is the analytical standard of Acetoacetic acid (lithium). This product is intended for research and analytical applications. Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-176987

TG (18:0_18:1_20:4)	Endogenous Metabolite	Metabolic Disease
TG (18:0_18:1_20:4) is a monoarachidonic triglyceride, belonging to the triacylglycerol lipid class.

HY-176985

TG (18:1_20:2_20:4)	Endogenous Metabolite	Metabolic Disease
TG (18:1_20:2_20:4) is a monoarachidonic triglyceride, belonging to the triacylglycerol lipid class.

HY-176982

TG (16:0_16:1_20:4)	Endogenous Metabolite	Metabolic Disease
TG (16:0_16:1_20:4) is a monoarachidic acid triglyceride, belonging to the triacylglycerol lipid class.

HY-176983

TG (16:0_18:2_20:4)	Endogenous Metabolite	Metabolic Disease
TG (16:0_18:2_20:4) is a monoarachidonic triglyceride, belonging to the triacylglycerol lipid class.

HY-176984

TG (18:0_18:2_20:4)	Endogenous Metabolite	Metabolic Disease
TG (18:0_18:2_20:4) is a monoarachidonic triglyceride, belonging to the triacylglycerol lipid class.

HY-176981

TG (18:2_20:3_20:4)	Endogenous Metabolite	Metabolic Disease
TG (18:2_20:3_20:4) is a monoarachidonic triglyceride, belonging to the triacylglycerol lipid class.

HY-176986

TG (16:0_18:1_20:4)	Endogenous Metabolite	Metabolic Disease
TG (16:0_18:1_20:4) is a monoarachidic acid triglyceride, belonging to the triacylglycerol lipid class.

HY-176988

TG (18:0_20:1_20:4)	Endogenous Metabolite	Metabolic Disease
TG (18:0_20:1_20:4) is a monoarachidonic triglyceride, belonging to the triacylglycerol lipid class.

HY-176989

TG (16:0_16:0_20:4)	Endogenous Metabolite	Metabolic Disease
TG (16:0_16:0_20:4) is a monoarachidic acid triglyceride, belonging to the triacylglycerol lipid class.

HY-165105

1,3-Dioleoyl-2-decanoyl glycerol TG(18:1/10:0/18:1); 1,3-Dioleoyl-2-caproyl glycerol; 1,3-Olein-2-caprin	Others	Others
1,3-Dioleoyl-2-decanoyl glycerol (TG(18:1/10:0/18:1)) is a compound that was investigated in the study of triglyceride composition in human milk and infant formula. The analysis and comparison of the compound using a specific chromatography-mass spectrometry technique revealed differences in triglyceride content between human milk and infant formula.

HY-169473

1,2,3-Tri-13(E)-docosenoyl glycerol Tribrassidin; TG(22:1/22:1/22:1)	Drug Derivative	Metabolic Disease
1,2,3-Tri-13(E)-docosenoyl glycerol (Tribrassidin; TG(22:1/22:1/22:1)) is an orally consumable triglyceride. 1,2,3-Tri-13(E)-docosenoyl glycerol was added to the diet of rats by mixing it with corn oil and undergoing ester exchange to improve its digestion and absorption .

HY-N8353

Stachybotramide	Others	Metabolic Disease
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) to very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .

Cat. No.	Product Name

HY-L182

Fatty Acids Compound Library	285 compounds
Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases. MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Fatty Acids Compound Library

285 compounds

Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.

MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Cat. No.	Product Name	Target	Research Area

HY-117110

Arginylproline H-Arg-Pro-OH	Proton Pump	Metabolic Disease
Arginylproline (H-Arg-Pro-OH) is a dipeptide consisted of arginine and proline. Arginylproline reduces intracellular triglyceride (TG) levels stimulated by Oleic acid (HY-N1446), through the peptide transporter 1 (PepT1) pathway .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-112540B

Acetoacetic acid sodium	Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .

HY-112540

Acetoacetic acid 4 Publications Verification	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .

HY-112540A

Acetoacetic acid lithium 4 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-N15875

18:1-18:1-C11 BODIPY 505/515 TG	Structural Classification Lipid	Fluorescent Dye
18:1-18:1-C11 BODIPY 505/515 TG is a fluorescently-labeled triglyceride that can be used as a fluorescent probe (Ex/Em = 495/503 nm).

HY-N15883

18:1-C11 BODIPY 505/515-C11 BODIPY 505/515 TG	Lipid	Fluorescent Dye
18:1-C11 BODIPY 505/515-C11 BODIPY 505/515 TG is a fluorescently-labeled triglyceride that can be used to measure triacylglycerol hydrolases (Ex/Em = 495/503 nm) .

HY-N15876

18:1-6:0 DNP-C11 BODIPY 505/515 TG	Lipid	Fluorescent Dye
18:1-6:0 DNP-C11 BODIPY 505/515 TG is a fluorescently-labeled triglyceride that can be used to study the effects of phosphoinositides (Ex/Em = 495/503 nm) .

HY-N11551

Salvifaricin	Artemisia frigida Willd. Terpenoids Labiatae Diterpenoids Plants Source Classification	Others
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-N8214

Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside	Cardiovascular Disease Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	Others
Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside is a bioactive constituent that can be found in the seeds of Lepidium apetalum Willd. Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside exhibits significant triglyceride (TG)-lowering effects in HepG2 cells .

HY-N7907

Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside	Leguminosae Phenols Polyphenols Sphaerophysa salsula (Pall.) DC. Plants	Others
Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside is a natural product that can be obtained from sphaerophysa salsula. Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside inhibits triglyceride (TG) accumulation in 3T3-L1 adipocytes .

HY-112540AR

Acetoacetic acid lithium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Acetoacetic acid (lithium) (Standard) is the analytical standard of Acetoacetic acid (lithium). This product is intended for research and analytical applications. Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-N8353

Stachybotramide	Natural Products Microorganisms Source Classification	Others
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) to very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .

Cat. No.	Product Name	Chemical Structure

HY-W015600S

2-Acetamidophenol-d3

2-Acetamidophenol-d₃ (Orthocetamol-d₃) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-115705

1,2,3-Tri-10(Z)-heptadecenoyl glycerol
1,2,3-Tri-10(Z)-heptadecenoyl glycerol (TG(17:1/17:1/17:1)) is a biochemical assay reagent, which can be used as an internal standard for the quantification of biological triglyceride .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

triglyceride (TG)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products